3,4-Diaminopiridina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "3,4-Diaminopiridina" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

4^th place

9^th place

799^th place

22^nd place

2web.archive.org

1^st place

1^st place

6^th place

8^th place

1dailymail.co.uk

219^th place

74^th place

archive.org

AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine., Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement, in Muscle Nerve, vol. 24, n. 9, 2001, pp. 1236–1238, DOI:10.1002/mus.1139, PMID 11494280.

dailymail.co.uk

Daniel Martin, Hospitals are forced to use unlicensed medicines to save millions, su Daily Mail, 27 settembre 2010. URL consultato il 28 settembre 2010 (archiviato il 28 settembre 2010).

doi.org

dx.doi.org

AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine., Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement, in Muscle Nerve, vol. 24, n. 9, 2001, pp. 1236–1238, DOI:10.1002/mus.1139, PMID 11494280.
Lundh H, Nilsson O, Rosen I, Johansson S., Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome, in Acta Neurol Scand, vol. 88, n. 2, 1993, pp. 136–140, DOI:10.1111/j.1600-0404.1993.tb04205.x, PMID 8213058.
Quartel A, Turbeville S, Lounsbury D, Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment, in Curr Med Res Opin, vol. 26, n. 6, giugno 2010, pp. 1363–75, DOI:10.1185/03007991003745209, PMID 20377318.
Argov Z, Management of myasthenic conditions: nonimmune issues, in Curr. Opin. Neurol., vol. 22, n. 5, ottobre 2009, pp. 493–7, DOI:10.1097/WCO.0b013e32832f15fa, PMID 19593127.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C, Aminopyridines for symptomatic treatment in multiple sclerosis, in Cochrane Database Syst Rev, n. 4, 2002, pp. CD001330, DOI:10.1002/14651858.CD001330, PMID 12804404.

nih.gov

ncbi.nlm.nih.gov

AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine., Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement, in Muscle Nerve, vol. 24, n. 9, 2001, pp. 1236–1238, DOI:10.1002/mus.1139, PMID 11494280.
Lundh H, Nilsson O, Rosen I, Johansson S., Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome, in Acta Neurol Scand, vol. 88, n. 2, 1993, pp. 136–140, DOI:10.1111/j.1600-0404.1993.tb04205.x, PMID 8213058.
Quartel A, Turbeville S, Lounsbury D, Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment, in Curr Med Res Opin, vol. 26, n. 6, giugno 2010, pp. 1363–75, DOI:10.1185/03007991003745209, PMID 20377318.
Argov Z, Management of myasthenic conditions: nonimmune issues, in Curr. Opin. Neurol., vol. 22, n. 5, ottobre 2009, pp. 493–7, DOI:10.1097/WCO.0b013e32832f15fa, PMID 19593127.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C, Aminopyridines for symptomatic treatment in multiple sclerosis, in Cochrane Database Syst Rev, n. 4, 2002, pp. CD001330, DOI:10.1002/14651858.CD001330, PMID 12804404.

oadoi.org

Lundh H, Nilsson O, Rosen I, Johansson S., Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome, in Acta Neurol Scand, vol. 88, n. 2, 1993, pp. 136–140, DOI:10.1111/j.1600-0404.1993.tb04205.x, PMID 8213058.
Quartel A, Turbeville S, Lounsbury D, Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment, in Curr Med Res Opin, vol. 26, n. 6, giugno 2010, pp. 1363–75, DOI:10.1185/03007991003745209, PMID 20377318.
Argov Z, Management of myasthenic conditions: nonimmune issues, in Curr. Opin. Neurol., vol. 22, n. 5, ottobre 2009, pp. 493–7, DOI:10.1097/WCO.0b013e32832f15fa, PMID 19593127.
Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C, Aminopyridines for symptomatic treatment in multiple sclerosis, in Cochrane Database Syst Rev, n. 4, 2002, pp. CD001330, DOI:10.1002/14651858.CD001330, PMID 12804404.

web.archive.org

Firdapse, su ema.europa.eu, European Medicines Agency. URL consultato il 28 settembre 2010 (archiviato dall'url originale il 20 settembre 2018).
Daniel Martin, Hospitals are forced to use unlicensed medicines to save millions, su Daily Mail, 27 settembre 2010. URL consultato il 28 settembre 2010 (archiviato il 28 settembre 2010).